Research by condition

Alcohol use disorder

Problem drinking that is hard to control despite harm.

PsiloAtlas editorial · AI-assisted research summary. Not clinical or medical review. How we research and review

First published October 31, 2026 · Last substantive update November 4, 2026 · Cited sources checked November 4, 2026

What each study tested

Each study is listed with the substance it tested. Results for one substance do not apply to another.

Psilocybin

Bogenschutz et al., JAMA Psychiatry, 2022

Design: Double-blind randomized trial: 12 weeks of psychotherapy plus two medication sessions of psilocybin or an antihistamine (diphenhydramine).
Who took part: 95 adults aged 25 to 65 with alcohol dependence.
Findings: Over 32 weeks, heavy-drinking days averaged 9.7% with psilocybin versus 23.6% with the antihistamine.
Limitations: Single trial; an antihistamine is easy to tell apart from psilocybin, which can weaken blinding.

Approval and access, by substance

Research results are not the same as approved or available treatment.

Psilocybin

Not approved by the FDA for any use, and listed in federal Schedule I. Legal adult access in the US exists through Oregon's licensed service centers and Colorado's licensed healing centers, and through clinical trials. Those state programs are not medical treatment programs and do not diagnose or treat conditions. Some countries have separate legal pathways; see the Legal section.

Sources: US Code of Federal Regulations, 21 CFR 1308.11 (Schedule I); Oregon Health Authority, Oregon Psilocybin Services; Colorado Natural Medicine Division, accessing regulated natural medicine

Next steps

General information, not medical advice. Talk to a doctor before any treatment, especially if you take medication or have heart or mental-health conditions.